Immunogen's cancer treatment candidate fails to meet the primary endpoint in a phase 3 trial.
Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.
Horizon Pharma's stock price skyrockets after the Dublin-based biotech reports positive results for a new drug to treat a rare but devastating eye disease.
And why I won't recommend any other stocks in these markets, right now.
Shares of Sarepta Therapeutics surge after the company announces an early stage study of a gene-therapy treatment that could benefit patients with a rare form of muscular dystrophy shows promising results.
Quick takes on fourth-quarter results from these 3 biotech names.
Here's how to trade XLRN stock right now.
France's Ipsen agrees to buy Clementia Pharmaceuticals in a deal worth up to $1.31 billion.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.